In the News: The Placebo Effect

The placebo effect is a beneficial health outcome resulting from a person’s anticipation that an intervention—pill, procedure, or injection, for example—will help them. A clinician’s style in interacting with patients also may bring about a positive response that is independent of any specific treatment.

According to a recent study published in the journal PLoS One, placebos given without deception improved symptoms of irritable bowel syndrome (IBS).

Source: http://nccam.nih.gov/news/2010/122210.htm?nav=rss

chemical screening

Echinacea

This fact sheet provides basic information about the herb echinacea—common names, uses, potential side effects, and resources for more information. There are nine known species of echinacea, all of which are native to the United States and southern Canada. The most commonly used, Echinacea purpurea, is believed to be the most potent.

What Echinacea Is Used For

  • Echinacea has traditionally been used to treat or prevent colds, flu, and other infections.
  • Echinacea is believed to stimulate the immune system to help fight infections.
  • Less commonly, echinacea has been used for wounds and skin problems, such as acne or boils.

Source: http://nccam.nih.gov/health/echinacea/ataglance.htm?nav=rss

chemical listing research chemicals library chemical library price

Study compares year-long effectiveness of four weight-loss plans

The very low carbohydrate diet known as the Atkins diet may contribute to greater weight loss than higher carbohydrate plans without negative effects such as increased cholesterol. Christopher Gardner, Ph.D., and colleagues at Stanford University conducted an NCCAM-funded study of 311 pre-menopausal women, all of whom were overweight or obese. Each woman was randomly assigned to one of four diets.

Source: http://nccam.nih.gov/research/results/spotlight/030607.htm?nav=rss

See here Look at here More information

In the News: Placebo Effect

Recently, several news outlets have been highlighting research studies of the placebo effect. The placebo response can be defined as the benefit patients receive from a treatment that has no active components. Researchers are using innovative study designs to untangle the complexities of the placebo effect.

Source: http://nccam.nih.gov/news/2012/011012.htm?nav=rss

Learn more chemical catalogs chemical compound library

Menopausal Symptoms and CAM

This fact sheet will provide information on menopausal symptoms and complementary and alternative medicine (CAM) based on findings from a 2005 National Institutes of Health State-of-the-Science conference on the management of menopause-related symptoms, as well as resources for more information.

Source: http://nccam.nih.gov/health/menopause/menopausesymptoms.htm?nav=rss

chemical compound listing chemical listing research chemicals library

CAM Use in Children

Complementary and alternative medicine (CAM) is a group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. As with adults, a wide range of CAM therapies are used in children, including herbs and dietary supplements, massage, acupuncture, chiropractic care, naturopathy, and homeopathy. This fact sheet includes issues to consider and resources for more information when making decisions about CAM use and children.

Source: http://nccam.nih.gov/health/children/index.htm?nav=rss

chemical compound library

Reducing aluminosilicate scale in the bayer process

The invention provides a method of inhibiting the accumulation of DSP scale in the liquor circuit of Bayer process equipment. The method includes adding one or more particular silane based small molecules to the liquor fluid circuit. These scale inhibitors reduce DSP scale formation and thereby increase fluid throughput, increase the…

Source: http://www.freshpatents.com/-dt20120614ptan20120148462.php

Look at here More information Learn more

GSK1292263 GPR inhibitor of second-line chemotherapy according to WHO or RECIST criteria

Roven adenocarcinoma of the stomach that U palliative chemotherapy had again. No phase III trial have been identified. A total of 696 patients with locally advanced gastric cancer and / or metastatic GSK1292263 GPR inhibitor were evaluated for response and toxicity Tons of second-line chemotherapy according to WHO or RECIST criteria. No tests in patients with adenocarcinoma of the feeder Hre. The taxanes, irinotecan, 5-FU oral agents such as capecitabine or S 1, platinum compounds, epirubicin and mitomycin C as second-line treatment tested. Be used in spite of paclitaxel, docetaxel, irinotecan, and S 1 as a single agent, most studies examined the combination therapy. Taxanes are commonly used in a second-line treatment combination of irinotecan, platinum derivatives, agents and 5-FU Including Lich capecitabine and S 1 followed used.
Taxanes Taxanes bind and stabilize microtubules, which were in cell cycle arrest, and these Fingolimod 162359-56-0 agents are used in the front for AGC. Of nine studies that the R Of taxanes in the second-line chemotherapy, paclitaxel 4 and 5 survey examined docetaxel reported. Paclitaxel was used as monotherapy or in combination with a platinum agent. Paclitaxel alone was used in divided doses for patients with poor PS. Weekly paclitaxel was used at 70 mg/m2 in heavily pretreated patients. The efficacy as second-line chemotherapy has been shown by a 4% RR and 5.1 months OS. Leukopenia grade 3 or 4 was found in 23% of patients. Chang et al. reported the efficacy and safety of paclitaxel 200 mg/m2 plus carboplatin AUC 6 in patients previously treated with FP MCO.
The RR of this system was 22% with a median PFS of 14 weeks and without a median overall survival of 32 weeks. However, grade 3 or 4 neutropenia in 40% of patients developed, and a dose adjustment was proposed. The h Most frequent non-h Dermatological toxicity t was neuropathy and joint pain. Combinations of paclitaxel and cisplatin were also investigated. Lee et al. 145 mg/m2 of paclitaxel 60 mg/m2 cisplatin pretreated patients used with FP hospitalized. The RR in this study was 28% with a median overall survival of 9.1 months. Neutropenia of grade 3 or h To her in 9% of patients. A Ern Currency, the h Dose of 175 mg/m2 paclitaxel here by cisplatin 70 mg/m2 every 3 weeks had an RR of 10% and a median survival time of 7.5 months in previously treated patients with AGC-5-FU.
The h Most frequent complication was neutropenia, with grade 3 or 4 was observed in 26% of neutropenic patients. Docetaxel has been used for the AGC as monotherapy or in combination with various other medications. Docetaxel 75 mg/m2 every 3 weeks produced an overall RR of 16% and a median overall survival of 8.3 months for patients who do not have the first-line treatment with PF, 18% of patients developed grade 3 or 4 neutropenia. The percentage of patients with non-dermatological toxicity t h grade 3 orworse were: asthenia, diarrhea and peripheral sensory neuropathy. Kim et al. given docetaxel 75 mg/m2 and cisplatin 60 mg/m2 every 3 weeks and found that 32% theRRwas amedianOSof at 7.8 months. The h Most frequent toxicity t grade 3 or 4 of this plan was neutropenia, 51%, followed by leukopenia and followed oral mucositis. In another Hnlichen study by Park et al, docetaxel 60 mg/m2 and cisplatin 60 mg/m2 every 3 weeks in patients who do not have an AGC System 5-FU

December 1 Is World AIDS Day

Many people infected with HIV or living with AIDS may be considering the use of complementary and alternative medicine (CAM) to boost their immune system; treat complications of disease; or cope with side effects of conventional medications. This information may be of interest.

Source: http://nccam.nih.gov/news/thismonth/december.htm?nav=rss

chemical catalogs chemical compound library chemical compound listing